Mirum Pharmaceuticals (NASDAQ:MIRM) Stock: Insider Laura Brege Sells 14,167 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) Director Laura Brege sold 14,167 shares of the business’s stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $94.21, for a total transaction of $1,334,673.07. Following the transaction, the director owned 15,703 shares of the company’s stock, valued at $1,479,379.63. This represents a 47.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Mirum Pharmaceuticals Stock Performance

NASDAQ:MIRM traded up $0.66 during mid-day trading on Friday, hitting $93.99. The company’s stock had a trading volume of 331,049 shares, compared to its average volume of 616,358. Mirum Pharmaceuticals, Inc. has a 1 year low of $63.23 and a 1 year high of $130.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.07 and a quick ratio of 1.98. The stock has a market cap of $6.14 billion, a price-to-earnings ratio of -6.08 and a beta of 0.75. The business’s fifty day moving average is $88.79 and its two-hundred day moving average is $98.41.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.38). The company had revenue of $185.72 million for the quarter, compared to analyst estimates of $178.07 million. Mirum Pharmaceuticals had a negative return on equity of 97.25% and a negative net margin of 134.75%. Mirum Pharmaceuticals’s revenue for the quarter was up 39.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.05 earnings per share. Analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.47 EPS for the current fiscal year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Jupiter Topco LLC purchased a new stake in Mirum Pharmaceuticals in the 2nd quarter worth $691,672,000. BlackRock Inc. purchased a new position in Mirum Pharmaceuticals during the second quarter valued at $513,945,000. William Blair Investment Management LLC purchased a new position in Mirum Pharmaceuticals during the second quarter valued at $164,453,000. Janus Henderson Group PLC lifted its holdings in Mirum Pharmaceuticals by 14.5% during the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock valued at $641,764,000 after purchasing an additional 880,505 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in Mirum Pharmaceuticals during the second quarter valued at $78,434,000.

Wall Street Analyst Weigh In

MIRM has been the topic of several analyst reports. Citigroup raised their target price on Mirum Pharmaceuticals from $184.00 to $194.00 and gave the stock a “buy” rating in a report on Wednesday. Royal Bank Of Canada reissued an “outperform” rating and issued a $155.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 4th. Stifel Nicolaus upped their price objective on Mirum Pharmaceuticals from $136.00 to $156.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th. Robert W. Baird upped their price objective on Mirum Pharmaceuticals from $123.00 to $130.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 29th. Finally, UBS Group set a $137.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $155.56.

View Our Latest Stock Analysis on MIRM

About Mirum Pharmaceuticals

(Get Free Report)

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.

Featured Articles

Insider Buying and Selling by Quarter for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.